Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

Especially high volume was seen for the $50 strike put option expiring January 16, 2026, with 2,002 contracts trading so far today, representing approximately 200,200 underlying shares of SLNO.

Soleno Therapeutics, Inc. SLNO has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some ...

Soleno Therapeutics, Inc. (SLNO) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

The average one-year price target for Soleno Therapeutics (NASDAQ:SLNO) has been revised to 12.58 / share. This is an increase of 37.04% from the prior estimate of 9.18 dated July 5, 2023. The ...